|

Cell Proteins May Predict Mesothelioma Prognosis

3193137_dna7

A cell protein devoted to regulating water transport and another related to DNA replication could be important keys to improved mesothelioma prognosis.

The American Cancer Society has released the results of a study on the relationship between a protein known as Aquaporin 1 (AQP1), which regulates water movement through the cell membrane, and treatment effectiveness for patients with mesothelioma.  At the same time, an international research team has also found a correlation between mesothelioma prognosis and the expression of the protein TIF-2.

Both of these new studies represent a relatively new approach to the treatment of mesothelioma, one focused on manipulating the complex inner workings of cells.  The Australian research teams that conducted the multi-center AQP1 study examined the AQP1 levels in two groups of mesothelioma patients – 80 patients who had undergone radical mesothelioma surgery (extrapleural pneumonectomy) and 56 patients who underwent more conservative treatments.

For both groups of patients, expression of AQP1 in 50% or more of cells in the tissue sample was associated with “significantly enhanced survival.”  Among mesothelioma patients who had undergone EPP, those in the higher AQP1 category survived 30.4 months compared with 9.4 months in the lower AQP1 group.  Among the more conservatively-treated mesothelioma patients, higher AQP1 levels resulted in survival rates that were three times higher than those with lower AQP1 – 15 months as opposed to 5 months. The survival results appeared to be independent of any other traditional mesothelioma prognostic factors, including histologic subtype, pathologic stage, sex, and age at diagnosis.

The results prompted the research team to recommend that “immunohistochemical labeling for AQP1 should be included in the routine histopathologic workup” for all mesothelioma patients. They further predict that chemicals which can either promote or block the cellular expression of AQP1 “may become useful for treatment.”

In a separate international study, researchers looking at TIF-2, a protein found in the cell nucleus that is associated with DNA replication, say they are the first to confirm a correlation between TIF-2 expression and improved mesothelioma prognosis.  In the 89 mesothelioma tumor biopsies studied, those with low TIF-2 expression survived a median of 9 months, while the median survival for those with higher TIF-2 expression was 20 months. Because mesothelioma is a fast-growing cancer, the ability to predict prognosis can be especially crucial, allowing doctors to tailor treatments for better results.

Sources:

Kao, SC et al, “Aquaporin 1 is an independent prognostic factor in pleural malignant mesothelioma”, October 21, 2011, Cancer, Epub head of print.
Jennings, CJ, “Sustained Expression of Steroid Receptor Coactivator SRC-2/TIF-2 is Associated with Better Prognosis in Malignant Pleural Mesothelioma”, October 18, 2011, Journal of Thoracic Oncology, Epub ahead of print.

Similar Posts

  • | |

    Mesothelioma survivor Paul Kraus, alive and well 19 years after writing “Surviving Mesothelioma and Other Cancers

    Paul Kraus is considered the longest documented mesothelioma survivor in the world. He was diagnosed in 1997 with mesothelioma so widespread that he was given little hope of survival. Not willing to give up, he worked with a team of doctors to create his own tailored treatment protocol. This protocol included dramatic life style change, experimental therapies, dietary changes, mind-body medicine, and other modalities. Paul was fortunate. The protocol he and his doctors created helped him keep the mesothelioma in check. His book “Surviving Mesothelioma and Other Cancers: A Patient’s Guide” details his cancer voyage, the decisions he made, and his philosophies about health and healing. This book is now the best-selling mesothelioma book in the world and has inspired…

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • |

    Mesothelioma Still Rising Despite Ban in Ireland

    A study in Ireland confirms that it can take many years for a ban on asbestos to have a measurable impact on a country’s rates of malignant mesothelioma. Mesothelioma is the most serious of a list of diseases – including lung cancer, pleural plaques, asbestosis, and others – linked with exposure to asbestos dust. Affecting the linings around the lungs and other organs, mesothelioma is often resistant to most cancer treatments and may be fatal within a year of diagnosis. According to the International Ban Asbestos Secretariat, Ireland is one of 55 countries that have enacted some type of asbestos ban. However, although Ireland banned asbestos in 2000, a new study published in Cancer Epidemiology shows that incidence of the…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Website Aims to Protect Homeowners from Mesothelioma

    Australia’s Cancer Council is trying to educate home renovators about their risk for mesothelioma with a new e-learning course. Australia has one of the highest per capita rates of mesothelioma in the world, largely because of several asbestos mining operations that were once located there. Although asbestos has been banned from building products in Australia since 1989, asbestos-linked diseases like mesothelioma, lung cancer, and asbestosis continue to pose a serious health concern. While mesothelioma has traditionally occurred among people exposed to asbestos on the job, Australia is now bracing for another “wave” of mesothelioma victims among homeowners who encounter asbestos while doing their own renovation projects. Cancer Council Australia has launched “kNOw asbestos in your home” in an effort to…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…